Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 354

1.

As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout.

Tausche AK, Christoph M, Forkmann M, Richter U, Kopprasch S, Bielitz C, Aringer M, Wunderlich C.

Rheumatol Int. 2014 Jan;34(1):101-9. doi: 10.1007/s00296-013-2857-2. Epub 2013 Sep 12.

PMID:
24026528
2.

An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.

Huang X, Du H, Gu J, Zhao D, Jiang L, Li X, Zuo X, Liu Y, Li Z, Li X, Zhu P, Li J, Zhang Z, Huang A, Zhang Y, Bao C.

Int J Rheum Dis. 2014 Jul;17(6):679-86. doi: 10.1111/1756-185X.12266. Epub 2014 Jan 28.

PMID:
24467549
3.

Diabetes and gout: efficacy and safety of febuxostat and allopurinol.

Becker MA, MacDonald PA, Hunt BJ, Jackson RL.

Diabetes Obes Metab. 2013 Nov;15(11):1049-55. doi: 10.1111/dom.12135. Epub 2013 Jun 12.

4.

The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.

Jackson RL, Hunt B, MacDonald PA.

BMC Geriatr. 2012 Mar 21;12:11. doi: 10.1186/1471-2318-12-11.

5.

Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.

Hatoum H, Khanna D, Lin SJ, Akhras KS, Shiozawa A, Khanna P.

Postgrad Med. 2014 Mar;126(2):65-75. doi: 10.3810/pgm.2014.03.2741.

PMID:
24685969
6.

Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.

Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C.

J Rheumatol. 2009 Jun;36(6):1273-82. doi: 10.3899/jrheum.080814. Epub 2009 Mar 13.

PMID:
19286847
7.

Increase in thyroid stimulating hormone levels in patients with gout treated with inhibitors of xanthine oxidoreductase.

Perez-Ruiz F, Chinchilla SP, Atxotegi J, Urionagüena I, Herrero-Beites AM, Aniel-Quiroga MA.

Rheumatol Int. 2015 Nov;35(11):1857-61. doi: 10.1007/s00296-015-3355-5. Epub 2015 Sep 5.

PMID:
26342297
8.

Febuxostat compared with allopurinol in patients with hyperuricemia and gout.

Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N.

N Engl J Med. 2005 Dec 8;353(23):2450-61.

9.

Febuxostat for treating chronic gout.

Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD008653. doi: 10.1002/14651858.CD008653.pub2. Review.

10.

Preservation of renal function during gout treatment with febuxostat: a quantitative study.

Whelton A, MacDonald PA, Chefo S, Gunawardhana L.

Postgrad Med. 2013 Jan;125(1):106-14. doi: 10.3810/pgm.2013.01.2626.

PMID:
23391676
11.

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.

Becker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, Lademacher C.

Arthritis Res Ther. 2010;12(2):R63. doi: 10.1186/ar2978. Epub 2010 Apr 6.

12.

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.

Schumacher HR Jr, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N.

Arthritis Rheum. 2008 Nov 15;59(11):1540-8. doi: 10.1002/art.24209.

13.

Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.

Ernst ME, Fravel MA.

Clin Ther. 2009 Nov;31(11):2503-18. doi: 10.1016/j.clinthera.2009.11.033. Review.

PMID:
20109996
14.

Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.

Chohan S, Becker MA, MacDonald PA, Chefo S, Jackson RL.

Arthritis Care Res (Hoboken). 2012 Feb;64(2):256-61. doi: 10.1002/acr.20680.

15.

Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a U.S. payer perspective.

Gandhi PK, Gentry WM, Ma Q, Bottorff MB.

J Manag Care Spec Pharm. 2015 Feb;21(2):165-75.

16.

Lesinurad: A Review in Hyperuricaemia of Gout.

Deeks ED.

Drugs Aging. 2017 May;34(5):401-410. doi: 10.1007/s40266-017-0461-y. Review.

PMID:
28425024
17.

Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.

Singh JA, Akhras KS, Shiozawa A.

Arthritis Res Ther. 2015 May 12;17:120. doi: 10.1186/s13075-015-0624-3. Erratum in: Arthritis Res Ther. 2015;17:236.

18.

Urate-lowering therapy for gout: focus on febuxostat.

Love BL, Barrons R, Veverka A, Snider KM.

Pharmacotherapy. 2010 Jun;30(6):594-608. doi: 10.1592/phco.30.6.594. Review.

PMID:
20500048
19.

Allopurinol for chronic gout.

Seth R, Kydd AS, Buchbinder R, Bombardier C, Edwards CJ.

Cochrane Database Syst Rev. 2014 Oct 14;(10):CD006077. doi: 10.1002/14651858.CD006077.pub3. Review.

PMID:
25314636
20.

African American patients with gout: efficacy and safety of febuxostat vs allopurinol.

Wells AF, MacDonald PA, Chefo S, Jackson RL.

BMC Musculoskelet Disord. 2012 Feb 9;13:15. doi: 10.1186/1471-2474-13-15.

Supplemental Content

Support Center